@article{d37fa819ffad462a86223a27aac2aa6b,
title = "ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants",
abstract = "Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1–2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response.",
author = "Jeffrey Seow and Carl Graham and Sadie Hallett and Thomas Lechmere and Thomas Maguire and Isabella Huettner and Dan Cox and Hataf Khan and Suzy Pickering and Anele Waters and Chris Ward and Christine Mant and Michael Pitcher and Jo Spencer and Julie Fox and Michael Malim and Katherine Doores",
note = "Funding Information: This work was funded by Huo Family Foundation Award to M.H.M. and K.J.D.; MRC Genotype-to-Phenotype UK National Virology Consortium ([MR/W005611/1] to M.H.M. and K.J.D.); Fondation Dormeur , Vaduz for funding equipment to K.J.D.; Wellcome Trust Investigator Award ([ 106223/Z/14/Z ] to M.H.M.); and Wellcome Trust Multi-User Equipment Grant ([ 208354/Z/17/Z ] to M.H.M. and K.J.D.). C.G. and S.H. were supported by the MRC - KCL Doctoral Training Partnership in Biomedical Sciences ([ MR/N013700/1 ]). D.C. was supported by a BBSRC CASE in partnership with GlaxoSmithKline ([ BB/V509632/1 ]). This work and the Infectious Diseases Biobank (C.M.) were supported by the Department of Health via a National Institute for Health Research comprehensive Biomedical Research Centre award to Guy{\textquoteright}s and St Thomas{\textquoteright} NHS Foundation Trust in partnership with King{\textquoteright}s College London and King{\textquoteright}s College Hospital NHS Foundation Trust. This study is part of the EDCTP2 program supported by the European Union (grant number RIA2020EF-3008 COVAB to K.J.D., J.F., and M.H.M.). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. This project is supported by a joint initiative between the Botnar Research Centre for Child Health and the European and Developing Countries Clinical Trials Partnership (K.J.D. and J.F.). This research was funded, in whole or in part, by the Wellcome Trust ([ 106223/Z/14/Z ] and [ 208354/Z/17/Z ]). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. Funding Information: We thank Philip Brouwer, Marit van Gils, and Rogier Sanders for the Spike protein construct, Peter Cherepanov for S1 proteins from VOCs, Leo James and Jakub Luptak for the N protein, Wendy Barclay for providing the B.1.617.2 and B.1.1.529 Spike plasmids, and James Voss and Deli Huang for providing the HeLa-ACE2 cells. This work was funded by Huo Family Foundation Award to M.H.M. and K.J.D.; MRC Genotype-to-Phenotype UK National Virology Consortium ([MR/W005611/1] to M.H.M. and K.J.D.); Fondation Dormeur, Vaduz for funding equipment to K.J.D.; Wellcome Trust Investigator Award ([106223/Z/14/Z] to M.H.M.); and Wellcome Trust Multi-User Equipment Grant ([208354/Z/17/Z] to M.H.M. and K.J.D.). C.G. and S.H. were supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences ([MR/N013700/1]). D.C. was supported by a BBSRC CASE in partnership with GlaxoSmithKline ([BB/V509632/1]). This work and the Infectious Diseases Biobank (C.M.) were supported by the Department of Health via a National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's and St Thomas{\textquoteright} NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. This study is part of the EDCTP2 program supported by the European Union (grant number RIA2020EF-3008 COVAB to K.J.D. J.F. and M.H.M.). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. This project is supported by a joint initiative between the Botnar Research Centre for Child Health and the European and Developing Countries Clinical Trials Partnership (K.J.D. and J.F.). This research was funded, in whole or in part, by the Wellcome Trust ([106223/Z/14/Z] and [208354/Z/17/Z]). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. Conceptualization, K.J.D. J. Seow, and C.G.; Methodology, J. Seow, C.G. S.R.H. T.L. T.J.A.M. I.H. D.C. H.K. and S.P.; Formal analysis, K.J.D. J. Seow, C.G. S.R.H. H.K. I.H. and M.J.P.; Resources, R.R. A.W. C.C.W. C.M. M.J.P. and J. Spencer; Supervision, K.J.D. J.F. M.H.M. and J. Spencer; Writing – original draft, K.J.D. J. Seow, and C.G. All authors reviewed and edited the manuscript. The authors declare no competing interests. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = may,
day = "3",
doi = "10.1016/j.celrep.2022.110757",
language = "English",
volume = "39",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Elsevier BV",
number = "5",
}
